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The AMP-activated protein kinase (AMPK) is an evolutionarily con-
served enzyme that senses the energy status of the cell and regu-
lates fuel availability. AMPK is a heterotrimeric protein consisting of
catalytic a and regulatory b and c subunits; it is activated allosteri-
cally by an increase in the intracellular AMP⁄ATP ratio as well as by
phosphorylation on Thr172 by upstream kinases (1). Two upstream
AMPK kinases have been previously identiﬁed: LKB1 and Ca
2+⁄
calmodulin-dependent protein kinase kinase (CaMKK) (2, 3).
CaMKKb is expressed primarily in the brain and therefore the
Ca
2+mediated pathway may be the most relevant in neurones (4).
Recently, transforming growth factor-b-activated kinase (TAK1), a
member of the mitogen-activated protein kinase kinase kinase
family, has also been proposed as a candidate AMPK kinase in
mammalian cells (5). AMPK is ubiquitously expressed and plays a
major role in fatty acid and glucose metabolism (6). AMPK activity
in liver, fat, skeletal muscle and other tissues is affected by numer-
ous compounds (7) and activation of this enzyme, via stimulation
of catabolic pathways and inhibition of anabolic pathways, results
in an improved lipid and glucose proﬁle and in an improved insu-
lin-sensitivity status of the whole organism (1).
The role of AMPK in the regulation of body weight and energy
homeostasis is not limited to its actions in the peripheral tissues. In
recent years, AMPK has emerged as a nutrient and glucose sensor in
the hypothalamus (8, 9) and its role in appetite regulation has been
thoroughly investigated by several groups. AMPK is widely expressed
throughout the brain, including several areas controlling food intake
and neuroendocrine function such as the hypothalamus and the
hindbrain, with immunostaining revealing a mainly neuronal distri-
bution of the various AMPK isoforms (10). Hypothalamic AMPK is
inﬂuenced by energy intake and availability, as demonstrated by the
fact that fasting increases and re-feeding decreases its activity in
the hypothalamus (11). It is also affected by several orexigenic and
anorexigenic signals in the hypothalamus (Table 1) (7).
Effects of pharmacological⁄genetic modiﬁcations
of hypothalamic AMPK on food intake
The ﬁrst study to report the involvement of AMPK in appetite regu-
lation showed that activation of AMPK via injection of 5-amino-
4-imidazole carboxamide riboside (AICAR), a pharmacological
activator of AMPK, into either the third ventricle or directly into the
paraventricular nucleus of the hypothalamus signiﬁcantly increased
food intake (12). In a very meticulous study, Minokoshi et al. (11)
showed that the expression of dominant negative AMPK in the
hypothalamus was sufﬁcient to reduce food intake and body
weight, whereas constitutively active AMPK increased both.
Although these ﬁrst two studies and numerous following studies
conﬁrmed the involvement of the hypothalamic AMPK in the medi-
ation of the appetite-stimulating or appetite-inhibiting effects of
various agents, a recent study by Claret et al. (13) questioned some
of these concepts and suggested that more detailed cell- or hypo-
thalamic nucleus-speciﬁc studies are needed. Most of the studies
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AMP-activated protein kinase is a key enzyme in the regulation of energy metabolism. Its activa-
tion has pleiotropic effects in multiple tissues, including increased fatty acid oxidation, glucose
uptake and glycolysis, as well as the inhibition of fatty acid and glycogen synthesis and gluco-
neogenesis, and stimulation of mitochondrial biogenesis. Recently, the AMP-activated protein
kinase (AMPK) has also emerged as a regulator of appetite, contributing to the control of energy
metabolism at both cell and the whole body levels. Pharmacological and genetic activation or
inhibition of hypothalamic AMPK lead to increased or reduced food intake, respectively. AMPK
appears to play a role in hypothalamic glucose and nutrient sensing and numerous studies have
suggested a role for AMPK in mediating the orexigenic or anorexigenic effects of various endog-
enous and exogenous substances.
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hypothalamus or in speciﬁc nuclei. In addition, many studies have
used AICAR as an activator of AMPK and Compound C as an inhibi-
tor. Several studies now suggest that neither AICAR, nor Compound
C are speciﬁc to AMPK and other relevant related pathways could
be inﬂuenced by these pharmacological agents (4); therefore, stud-
ies using dominant negative or constitutively active AMPK mutants
or the most recent studies with cell-type speciﬁc silencing of AMPK
could provide a novel insight. To explore in more detail the speciﬁc
hypothalamic neurones where AMPK plays a role, a2 AMPK was
speciﬁcally knocked out in hypothalamic Agouti-related peptide
(AgRP) neurones or in hypothalamic pro-opiomelanocortin (POMC)
neurones via crossing mice with ﬂoxed a2 AMPK gene with mice
harbouring the Cre recombinase in AgRP and POMC promoters (13).
AgRP a2 AMPK-KO showed decreased body weight even though
there were no changes in food intake or energy expenditure and,
the difference in body weight was lost when the animals were fed
a high fat diet (HFD). POMC a2 AMPK-KO animals, showed unex-
pectedly increased body weight and adiposity, which was further
enhanced by a HFD. These ﬁndings could not be explained by
baseline morphological changes in the neurones or by the possible
studied compensatory mechanisms. AMPK is known to undergo
tissue-speciﬁc regulation and these ﬁndings point to a cell-speciﬁc
role for AMPK. Losing AMPK in orexigenic (AgRP) neurones leads to
reduced body weight whereas loss of the enzyme in anorexigenic
(POMC neurones) leads to increased body weight.
Energy-related AMPK changes
AMPK activity is regulated by intracellular energy levels, but it also
senses whole body energy levels because it is affected by short-
term (fasting and feeding acutely) and long-term energy signals
(chronic changes in diet-induced obesity (DIO). Fasting results in
activation of AMPK whereas re-feeding inhibits AMPK activity in
multiple hypothalamic regions in mice (11). Fasting and re-feeding
are characterised by changes in nutrients (e.g. glucose) and hor-
mones (e.g. insulin) levels, which could explain the effect on hypo-
thalamic AMPK. Several studies have demonstrated that
hypothalamic AMPK is regulated by blood glucose levels. Peripheral
or central hyperglycaemia inhibits AMPK in the arcuate nucleus
(ARC), the ventro- and dorso-mediobasal hypothalamus (VMH and
DMH), the paraventricular nucleus (PVN) and the lateral hypothala-
mus (LH) (11, 14). Insulin-induced hypoglycaemia and inhibition
of intracellular glucose utilisation through the administration of
2-deoxyglucose (2-DG) both increase hypothalamic AMPK activity
and food intake (14, 15). Concordantly, in neuronal cell lines and
ex-vivo hypothalamic cultures, low glucose and 2-DG increase
hypothalamic AMPK activity, similarly to the AMPK activator AICAR
(16, 17), whereas high glucose and pyruvate supplementation in
2-DG treated-cells decrease expression and phosphorylation of
AMPK through changes in intracellular ATP levels (16). Long-term
energy signals also appear to affect hypothalamic AMPK. DIO mice
have suppressed AMPK activity in the PVN of the hypothalamus
(18). The lower basal AMPK activity in PVN may be due to effects
of hyperinsulinaemia and⁄or hyperglycaemia, which suppress AMPK
activity in multiple hypothalamic nuclei (11, 15). AMPK is
suppressed to the level observed in leptin-treated chow-fed mice,
and there is no further effect of leptin (18). In mice, DIO alters the
effect of leptin on AMPK activity not only in the hypothalamus, but
also in the skeletal muscle (18, 19). However, when the ciliary neu-
rotrophic factor analogue (CNTFAx15), whose signalling pathway in
the hypothalamus partially overlaps with that of leptin, is given
i.c.v. it not only reduces food intake of DIO mice, but also further
suppresses hypothalamic AMPK activity, bypassing diet-induced
leptin resistance (20). Diabetic rats have enhanced AMPK activity,
despite their high glucose levels, which should suppress hypotha-
lamic AMPK. The activation of AMPK could contribute to their
hyperphagia and may be explained by the lower plasma levels of
leptin and insulin in these animals (21).
AMPK as a mediator of several orexigenic
and anorexigenic signals
Leptin has a tissue-speciﬁc effect on AMPK: in the skeletal muscle,
it stimulates AMPK activity whereas, in the hypothalamus, it has
the opposite effect, decreasing hypothalamic AMPK activity (11, 12,
22). These apparently paradoxical tissue-speciﬁc effects of leptin
contribute both to the overall positive effect of leptin on energy
homeostasis, leading to increased fatty acid oxidation in peripheral
tissue (23, 24) and to reduced appetite in the hypothalamus with
consequent reduction of body weight. Minokoshi et al. (11) studied
the effect of leptin in the speciﬁc hypothalamic nuclei and showed
that leptin inhibits AMPK activity in ARC and PVN. Furthermore,
inhibition of hypothalamic AMPK is necessary for leptin’s effects on
food intake and body weight, as constitutively active AMPK blocks
these effects. A more recent study conﬁrmed the importance of
AMPK in the effect of leptin as AICAR was able to reverse the
inhibitory effect of leptin on the electrical activity of glucose-
inhibited neurones (25). However, the selective AMPKa2-deﬁcient
POMC or AgRP neurones showed normal response to leptin in
another study (13).
Table 1. Compounds and Signals that Affect Hypothalamic AMP-Activated
Protein Kinase (AMPK) Activity.
Orexigenic signals
(activators of hypothalamic AMPK)
Anorexigenic signals
(inhibitors of hypothalamic AMPK)
Hypoglycaemia, 2-deoxyglucose
(14–17)
Glucose (11, 14)
Agouti-related peptide (11) Leptin (11)
Ghrelin (12, 27) Insulin (11)
Cannabinoids (27) C75 (46)
Glucocorticoids a-Lipoic acid (14)
Adiponectin (42) Metformin (17)
Low temperatures (53) Ciliary neurotrophic factor
analogue (20)
Thyroid hormones (50) a-melanocyte-stimulating hormone,
MT-II (a melanocortin 4
receptor agonist) (11, 73)
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decrease AMPK activity in PVN, whereas AgRP, a melanocortin
receptor antagonist, increased AMPK activity. Insulin i.c.v. inhibits
AMPK activity in multiple hypothalamic regions 3 h after injection
(11).
Ghrelin is a circulating growth hormone-releasing and appetite-
inducing brain-gut peptide with predominant expression in the gas-
tric mucosa, but low-level widespread expression throughout the
body (26). Ghrelin stimulates hypothalamic AMPK following i.p.
injection (12, 27) or i.c.v. injection (27), suggesting that AMPK acti-
vation might be part of its orexigenic effect. In addition, ghrelin
has direct peripheral actions in several organs, including the liver
and adipose tissue, and similar to leptin, has an opposite (inhibi-
tory) effect on the AMPK in these tissues (27).
To date, there is no explanation as to why some hormones have
tissue-speciﬁc effects on AMPK activity. This could possibly be due
to different AMPK upstream kinases or AMPK phosphatases being
affected in different tissues.
The upstream kinase by which ghrelin exerts its effects on AMPK
activity has not yet been reported. The only receptor so far identi-
ﬁed for ghrelin is the growth hormone secretagogue receptor type
1a, which is a Gq-PKC pathway-coupled receptor (28), and ghrelin
has been shown to induce Ca
2+ signalling in neuropeptide Y (NPY)
neurones in the ARC (29, 30). CaMKKb is regulated by intracellular
Ca
2+ levels (3, 31) and therefore constitutes a possible candidate in
mediating the effect of ghrelin on AMPK activity.
Both exogenous and endogenous cannabinoids stimulate appetite
in the hypothalamus via cannabinoid receptor type 1 (CB1) (32–34).
Furthermore, endocannabinoid hypothalamic levels change in
response to fasting and feeding (35) and seem to play an important
role in mediating the anorexigenic effects of leptin (36) and ghrelin
(37). We have shown that cannabinoids stimulate AMPK activity in
the hypothalamus, and this could explain their central orexigenic
effects (27). By contrast, they inhibit AMPK activity in the liver and
adipose tissue, which may lead to fuel, particularly fat, storage (27).
The combined effect of both central and peripheral signals would
therefore be increased food intake and lipid storage, leading to lipid
deposition and weight gain.
Glucocorticoids are also known to increase appetite and we have
shown in a rodent model of Cushing’s syndrome that the features
of the metabolic syndrome are associated with increased AMPK
activity in the hypothalamus (Fig. 1) (38). Corticosterone-treated
animals had ad libitum sucrose available to block the marked
catabolism caused by high-dose corticosterone-pellets. Sucrose-
drinking animals had lower hypothalamic AMPK activity compared
to saline-drinking control rats, conﬁrming the inhibitory effect of
sucrose on AMPK activity. Corticosterone administration counter-
acted this effect of sucrose and increased hypothalamic AMPK
activity to levels comparable with saline-drinking animals (Fig. 1A).
The effect of glucocorticoids on hypothalamic AMPK is possibly
mediated by endogenous cannabinoids because 2-arachydol-
glycerol (2-AG) (Fig. 1B) and anandamide contents were higher in
corticosterone-treated rats than in sucrose drinking control rats.
We also showed a dexamethasone-induced increase in AMPK in
primary rat hypothalamic cell cultures, suggesting a direct effect of
glucocorticoids on AMPK activity (Fig. 1C). Metformin, which has
previously been shown to inhibit hypoglycaemia-induced AMPK
(17), was also able to inhibit the stimulatory effect of dexametha-
sone in primary hypothalamic culture (38).
Adiponectin, an adipokine secreted exclusively by the white adi-
pose tissue, has been shown to stimulate fatty acid oxidation
through the activation of AMPK in the peripheral tissues (39–41).
However, a recent study shows that peripheral adiponectin also has
central effects in the hypothalamus as its trimer and hexamer
forms can enter the cerebrospinal ﬂuid (42). Surprisingly, and
apparently in disagreement with its well-assigned role as an anti-
diabetic hormone, adiponectin enhances AMPK activity in the ARC
after re-feeding, stimulates food intake and decreases energy
expenditure (42). Conversely, adiponectin-deﬁcient mice showed
decreased AMPK phosphorylation in the ARC, decreased food intake,
and increased energy expenditure, exhibiting resistance to high fat
diet-induced obesity. Serum and cerebrospinal ﬂuid adiponectin
levels increased during fasting and decreased during re-feeding,
suggesting a role for adiponectin as a starvation hormone. In this
guise, under fasting conditions, high adiponectin levels would
stimulate AMPK and food intake and would decrease energy expen-
diture, promoting fat storage. After re-feeding adiponectin levels
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Fig. 1. Effects of glucocorticoid treatment on hypothalamus. Hypothalamic
AMP-activated protein kinase (AMPK) (A) and hypothalamic endocannabinoid
(2-AG) content (B) in a rat model of Cushing’s syndrome (corticosterone
pellet for 2 weeks with sucrose-drinking, n = 6 per group) and appropriate
control groups (placebo pellet with saline- or sucrose-drinking). (C) AMPK
activity in primary hypothalamic cultures treated with dexamethasone 1 lM
for 6 h compared to control treatment (expressed as % of control).
*P < 0.05; **P < 0.01; ***P < 0.001 Modiﬁed from Christ-Crain et al. (38).
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intake and an increase in energy expenditure. Under fasting or after
re-feeding conditions, adiponectin levels correlate inversely to
serum leptin levels, and because leptin’s effect on hypothalamic
AMPK and food intake is apparently opposite to that of adiponec-
tin, Kubota et al. (42) conclude that a joint signal of the two hor-
mones regulates whole body energy homeostasis under these
conditions. These important ﬁndings contrast with previous data on
the role of peripheral adiponectin and point to a dissociated role
between peripheral adiponectin and central nervous system adipo-
nectin. Hormones such as leptin and ghrelin have opposite, tissue
speciﬁc effects in the hypothalamus and the peripheral organs (7),
whereas adiponectin appears to have a stimulatory effect on the
enzyme in all the different tissues studied. This very exciting study
points out once more the complexity of the systems that regulate
whole body metabolism and the necessity for further research in
this direction.
Metformin, an important anti-diabetic agent, stimulates AMPK in
the liver and in the muscle (43–45). In analogy with other hor-
mones, metformin has an opposite effect on AMPK in the hypothal-
amus. Chau-Van et al. (17) showed that metformin blocks the
AMPK phosphorylation induced by low glucose in primary cultures
of rat hypothalamic neurones. Consistently, metformin inhibited
NPY mRNA expression induced by low glucose conditions, whereas
no effect was present on POMC gene expression. These data could
provide a potential mechanism of action for the anorectic effects
of metformin (17).
C75, a fatty acid synthase (FAS) inhibitor, which causes weight
loss and anorexia, rapidly reduced the level of the phosphorylated
AMPKa subunit in the hypothalamus (46). It also reduced pAMPK
levels in fasted mice that had elevated hypothalamic pAMPK. AICAR
was able to reverse both the inhibitory effect on pAMPK and the
C75-induced anorexia (46).
a-Lipoic acid, an antioxidant that reduces food intake, also
inhibits AMPK activity in the hypothalamus (14). AICAR or expres-
sion of a constitutively active AMPK variant prevent its anorexigenic
effect (14).
Although there is evidence that thyroid hormones stimulate
AMPK and acetyl-CoA carboxylase (ACC) expression in rat skeletal
muscle (47, 48) and propylthiouracil (an inhibitor of thyroid hor-
mone synthesis) inhibits this effect (49), there are no conclusive
data about their effect on hypothalamic AMPK. Preliminary data
have shown that triiodothyronine increases AMPK activity in the
hypothalamus, offering a possible explanation for the hyperphagia
observed in hyperthyroid states (50).
The role of AMPK as an appetite mediator has also been investi-
gated in conditions known to affect food intake such as exercise
and low temperatures.
Exercise is known to inﬂuence appetite, but changes in energy
metabolism during or after exercise are probably not coordinated
by changes in hypothalamic AMPK as 1 h of strenuous exercise
in rats did not elicit signiﬁcant changes in hypothalamic AMPK
activity despite an increase in plasma ghrelin (51). Other exercise-
induced cytokines (e.g. IL-6) may also have had an effect on hypo-
thalamic AMPK and might have opposed the effect of increased
plasma ghrelin (52). The effects of exercise on food intake are also
exercise-type and time-dependent. Unfortunately, the effects of
exercise on food intake were not reported in this study (51).
Interestingly, AMPK has been shown to mediate cold-induced
resistance to anorexigenic signalling in the hypothalamus (53).
Feeding and insulin-induced anorexigenic responses are reduced by
exposure to cold, probably due to the cold-induced AMPK activation
and ACC inactivation. The insulin-induced inhibition of AMPK is also
impaired by cold-exposure. This study offers a plausible explanation
for the increased feeding noticed during cold-exposure which may
result, at least in part, from resistance to insulin and nutrient-
dependent anorexigenic signalling in the hypothalamus (53).
Downstream mediators of AMPK in hypothalamus
The mechanisms through which AMPK inﬂuences feeding behaviour
are not fully understood (Fig. 2). Changes in the expression of well-
known orexigenic and anorexigenic genes, such as NPY, POMC and
AgRP, have been reported with modulation of AMPK activity. Alter-
ations of hypothalamic AMPK activity augment changes in arcuate
neuropeptide expression induced by fasting and feeding (11). Over-
expressing DN-AMPK in mediobasal hypothalamus suppresses
mRNA expression of orexigenic neuropeptides, NPY and AgRP in
ARC, whereas overexpressing CA-AMPK enhances the fasting-
induced increase in expression of NPY and AgRP in ARC and mela-
nin-concentrating hormone in the lateral hypothalamus (11).
Low glucose levels in neuronal cell lines not only increased phos-
phorylation of AMPK, but also increased AgRP expression (16). High
glucose concentrations in ex vivo hypothalamus culture decreased
expression of both AgRP and NPY, whereas pyruvate supplementa-
tion suppressed 2-DG-induced AgRP expression (16). Glucose has
also been shown to inhibit AMPK activity in a POMC-expressing
hypothalamic cell line, with a resulting increase in expression of
POMC mRNA (54). By contrast, metformin, which blocks the AMPK
phosphorylation induced by low glucose, does not affect POMC
gene expression, but does inhibit the stimulation of NPY observed
in low glucose conditions (17). These changes in neuropeptide
expression are very likely to mediate, at least in part, the effects of
AMPK in appetite regulation.
The downstream pathways of AMPK in the hypothalamus may
involve the ACC-malonyl-CoA-carnitine palmitoyltransferase 1
(CPT1) pathway and the mammalian target of rapamycin (mTOR)
pathway. Some studies show that modulation of AMPK by leptin
(12), a-lipoic acid (14) or ghrelin (27) is associated with decreased
(leptin and a-lipoic acid) or increased (ghrelin) phosphorylation of
its downstream target ACC, leading to stimulation or inhibition of
ACC activity (Fig. 2). Activation of ACC, as a consequence of AMPK
inhibition, would lead to increased intracellular malonyl-CoA levels,
which would inhibit mitochondrial CPT1 and fatty acid oxidation. In
support of this mechanism, degradation of malonyl-CoA in the me-
diobasal hypothalamus of rats results in increased food intake and
progressive weight gain (55), whereas inhibition of CPT1 in the
hypothalamus suppresses food intake (56, 57).
The anorexigenic effect of leptin is mediated by inhibition of
AMPK, probably in a coordinate manner with the signal transducer
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activation of the hypothalamic STAT3 pathway is an absolute
requirement for the effects of leptin on food intake (58, 59). Leptin
increases STAT3 phosphorylation in all hypothalamic regions,
whereas its effect on AMPK activity is limited to ARC and PVH (11).
Furthermore, the effects of DN- and CA-AMPK could not be
explained by alterations in STAT3 tyrosine phosphorylation or pro-
tein level in the hypothalamus, suggesting that AMPK functions
either downstream of, or in a parallel pathway to, STAT3 to modu-
late its effects on food intake (11). Similarly to leptin, the effect of
CNTFAx15 on food intake and exspression of orexigenic peptides is
mediated by increased STAT3 phosphorylation in the ARC and sup-
pressed AMPK activity (20). Interestingly, SOCS3, an inhibitor of lep-
tin-STAT3 signalling, inhibits leptin activation of AMPK in primary
myotubes (60).
Another possible downstream target of AMPK in the hypothala-
mus is the mTOR pathway. AMPK affects protein synthesis in the
periphery through the mTOR-P70S6-kinase pathway (61). In the
hypothalamus, a direct link between the AMPK and mTOR has not
been proven but is tempting to think so because central treat-
ments with both leptin and leucine have been found to inhibit
food intake and reduce body weight through stimulation of this
pathway (62).
Role of AMPK in hypothalamic glucose sensing
Several studies have investigated the role of AMPK in glucose sens-
ing by specialised glucose-sensing neurones in the hypothalamus
and in the hormonal counter-regulatory response to hypoglycaemia.
Appropriate counter-regulatory response is crucial for recovery from
hypoglycaemia and AMPK activation appears to mediate this func-
tion (Fig. 3). Insulin-induced hypoglycaemia in rats increases AMPK
phosphorylation and a2AMPK activity in the ARC⁄VMH and PVN
(15). Inhibition of hypothalamic AMPK, either via Compound C or
dominant negative AMPK expression, inhibits the hypoglycaemia-
induced increase in the counter-regulatory hormones glucagon,
corticosterone and catecholamines, causing a severe and prolonged
hypoglycaemia (15). Consistent with this ﬁnding, VMH AMPK
down-regulation, via virus-assisted expression of short hairpin RNA
for aAMPK, resulted in suppressed glucagon and epinephrine
responses to acute hypoglycaemia (63). These rats required more
exogenous glucose to maintain glucose levels and showed signiﬁ-
cant reductions in endogenous glucose production (63). AICAR
administration in the VMH during a hyperinsulinaemic-hypoglycae-
mic clamp resulted in a signiﬁcant reduction in the amount of
exogenous glucose required by the rat to maintain the hypoglycae-
mic plateau (64). This effect is associated with a three- to four-fold
increase in hepatic glucose output, suggesting that the combination
of hypoglycaemia- and AICAR-induced AMPK activity results in a
marked stimulus to hepatic glucose production (64).
Recurrent hypoglycaemia can lead to a phenomenon known as
hypoglycaemia-associated autonomic failure (65). In this situation,
antecedent hypoglycaemia blunts the counter-regulatory hormone
response that normally restores normo-glycaemia (66). Single i.c.v.
injections of 2-DG increased both a1- and a2-AMPK activities in
ARC at 10 min, and increased AMPK activity persisted at 60 min
(67). When 2-DG was injected i.c.v. once a day for 4 days, inducing
recurrent neuroglucopaenia, hypothalamic a1- and a2AMPK
responses were markedly blunted at 10 min whereas normal activa-
tion was seen at 60 min, suggesting impaired or delayed AMPK
activation. Impaired counter-regulatory hormone responses were
partially restored by i.c.v. injection of AICAR before the 2-DG (67).
In another study, 3 days of recurrent insulin-induced hypoglyca-
emia resulted in an increase in the gene expression of a1- and
a2AMPK in the whole hypothalamus and in the VMH (68). Phos-
phorylation status of AMPK was not reported in this study and the
different model of recurrent hypoglycaemia used could explain the
apparent differences in results between the two studies (67, 68).
PI 3-kinase/PDK1 
Hypothalamic AMPK 
ACC 
Malonyl CoA  Acetyl CoA 
Long-chain Acyl CoA 
CPT1 
POMC  NPY 
AgRP 
PKB1 
TSC1/TSC2 
mTOR 
p70S6K 4E-BP1 
Fig. 2. Downstream targets of AMP-activated protein kinase (AMPK) in the hypothalamus. The effect of AMPK on the mammalian target of rapamycin (mTOR)
pathway (grey box and grey arrows) has not been directly proven in the hypothalamus. AMPK, AMP-activated protein kinase; POMC, pro-opiomelanocortin;
NPY, neuropeptide Y; AgRP, Agouti-related peptide; ACC, acetyl-CoA carboxylase; CPT1, carnitine palmitoyltransferase 1 (CPT1).
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ter-regulatory response (68).
Role of AMPK in the determination of hypothalamic
neuronal electrical activity
In addition to the effect of AMPK on the counter-regulatory
response control, AMPK also mediates the effects of glucose, and
possibly other hormones, on the electrical activity of hypothalamic
neurones.
Two types of glucose-sensing neurones have been identiﬁed.
Activity of glucose-inhibited (GI) neurones decreases in response to
increased glucose concentrations whereas glucose-excited neurones
increase their activity in response to increased glucose concentra-
tions (69). GI neurones are present in the VMN, in the ARC and in
the LH and partly overlap with the orexigenic NPY⁄AgRP and possi-
bly orexin neurones. GE neurones correspond in part to POMC neu-
rones in the VMN and possibly in ARC and to MCH neurones in the
LH (69). Mountjoy et al. (25) showed that, in GI neurones of the
basomedial hypothalamus (40% of NPY-expressing neurones are GI
neurones), the effect of large ﬂuctuations in glucose concentration
on electrical activity and Ca
2+ oscillation frequency is mediated
through changes in AMPK activity. The stimulatory effects of
decreased glucose on GI neurones were mimicked by AICAR and
blocked by Compound C. Similar data were shown with leptin. Lep-
tin suppressed the activity of GI neurones induced by low glucose
concentrations and this inhibitory effect was reversed by AICAR in
the majority of GI neurones (25). Forced changes in AMPK activity,
by application of either AICAR or Compound C, had no effect on
glucose-excited and non-glucose-responsive neurones (25). Based
on these studies, it has been suggested that AMPK plays a role in
the glucose sensing effect of GI neurones but not in GE neurones.
Claret et al. (13) showed that ARC POMC neurones are hyperpolar-
ised (inhibited) by reductions in extracellular glucose concentration.
Surprisingly, and in contrast with previous studies (70, 71), a
minority of ARC AgRP neurones were also inhibited by decreasing
glucose levels but not affected by increasing glucose concentrations
(13). POMC a2 AMPK-KO and AgRP a2 AMPK-KO neurones did not
change their ﬁring rates or their membrane potential in response to
glucose changes, suggesting a role for AMPK as a common glu-
cose-sensor in these neurones (13). By contrast, the depolarising
effect of leptin and the repolarising effect of insulin in a minority
of ARC POMC were maintained in POMC a2 AMPK-KO neurones.
Leptin did not have an effect on AgRP neurones whereas insulin
depolarised AgRP neurones and the effect was still present in AgRP
a2 AMPK-KO neurones. These data suggest AMPK-independent
pathways for these two anorexigenic hormones. This is partly in
contrast with other studies that have reported AMPK dependent
effects of leptin (25). It is important to emphasise that GE neurones
do not overlap completely with POMC neurones in the ARC
while the GI neurones do not completely overlap with NPY⁄AgRP
neurones. Indeed, Claret et al. (13) found that alterations in exter-
nal glucose levels did not alter the excitability of all ARC POMC
and AgRP neurones. The different results may be explained, in
addition to the different techniques and experimental setups, by
the presence of distinct subpopulations of GE and GI neurones
with different neuropeptide phenotypes, responses to hormonal
stimuli and, in some cases, different glucose-sensing mechanisms
Hypoglycaemia 
Hypothalamic AMPK 
Glucagon, 
Cathecolamines, 
Corticosterone 
Hepatic glucose output 
Liver 
Skeletal muscle 
Fatty acid oxidation 
glycogen synthesis 
Brown adipose tissue
Energy expenditure
White adipose tissue
Lipogenesis
Lipolysis
Ghrelin  Leptin, 
MT-II, 
Insulin, 
Glucose 
AICAR 
Fig. 3. Effects of different central treatments on peripheral metabolism through changes in hypothalamic AMP-activated protein kinase (AMPK). Intracerebro-
ventricular leptin, MT-II, insulin, glucose and 5-amino-4-imidazole carboxamide riboside (AICAR) treatment affect skeletal muscle metabolism through hypotha-
lamic AMPK (blue arrows). Hypoglycaemia stimulates hypothalamic AMPK and exerts a consequent counter-regulatory response with a ﬁnal effect on hepatic
glucose output (orange arrows). Central ghrelin inﬂuences white adipose tissue AMPK activity (purple arrows) and central adiponectin and a-lipoic acid admin-
istration change energy expenditure in brown adipose tissue (green arrows).
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AMPK activity also inﬂuences NO production and neuronal activ-
ity in GI neurones. The AMPK activator, AICAR, increases both NO
production and neuronal activity in GI neurones of the VMH (72).
Glucose and leptin suppress neuronal nitric oxide synthase-depen-
dent NO production in cultured VMH GI neurones, whereas insulin
stimulates it (72). The effects of decreased glucose and leptin are
blocked by inhibition of AMPK with Compound C, whereas the
effect of insulin is AMPK-independent. These data further suggest
that the effects of glucose and leptin in GI neurones are mediated
by the suppression of AMPK.
Role of hypothalamic AMPK in regulating peripheral
metabolism
One of the most interesting ﬁndings of the recent research into
hypothalamic regulation of appetite is the neuronal link between
the hypothalamus and the periphery. The hypothalamic regulation
of peripheral metabolism that had previously been recognised
seems now to extend to the AMPK as well (Fig. 3). Minokoshi et al.
(22) described that leptin treatment affects skeletal muscle AMPK
both directly and via the hypothalamic-sympathetetic nervous
system axis. The endogenous melanocortin system is implicated in
this effect because the central melanocortin receptor agonist MT-II
increases and melanocortin receptor antagonist SHU9119 decreases
AMPK phosphorylation in the skeletal muscle. This effect is
independent of their effect on food intake, as shown in pair-fed
animals (73).
In leptin-over-expressing transgenic mice on a HFD, muscle AMPK
phosphorylation and ACC phosphorylation are reduced compared
with standard diet leptin-over-expressing transgenic mice and are
comparable to HFD-non-transgenic mice. In these animals, leptin
i.c.v., in addition to transgenic hyperleptinaemia, is not able to
restore the impaired AMPK signalling because of the induced gener-
alised leptin resistance. However, MT-II i.c.v. signiﬁcantly augments
AMPK and ACC phosphorylation, suggesting that MT-II is a potent
AMPK activator in muscle, even in mice on a HFD (73). Central
adiponectin treatment also has effects in the periphery: i.c.v. injec-
tion of adiponectin results in decreased energy expenditure, possibly
as a result of a reduced expression of uncoupling protein-1 (UCP-1)
in brown adipose tissue (42). Central a-lipoic acid, which inhibits
hypothalamic AMPK activity, increases energy expenditure and UCP-
1 expression in brown adipose tissue (14). Co-administration of i.c.v.
AICAR prevents the effects of a-lipoic acid (14). We have obtained
preliminary data suggesting that i.c.v. treatment with ghrelin affects
adipose tissue AMPK activity (B. Kola, M. Christ-Crain, G. Wittmann,
F. Lolli, F. Amin, A. Grossman, C. Fekete, M. Korbonits, unpublished
data). This effect is supported by another study showing that
chronic central ghrelin treatment results in increased glucose utilisa-
tion rate of white and brown adipose tissue; these effects are inde-
pendent of ghrelin-induced hyperphagia (74). Central ghrelin
treatment has also been shown to inhibit, at least in part, indepen-
dently from the effect on food intake, the effects of i.c.v. leptin
treatment on fat weight, plasma insulin and glucose (75).
Interestingly, hypothalamic AMPK has also been implicated in the
regulation of muscle glycogen synthesis as i.c.v. AICAR treatment
increased both insulin-mediated and non insulin-mediated glycogen
synthesis (76). Central insulin infusion also increased muscle glyco-
gen synthesis. This effect was blocked by the co-administration of
glucose (76).
Hypothalamic AMPK, as described above, also mediates the coun-
ter-regulatory response to hypoglycaemia, increasing the release of
peripheral hormones such as corticosterone, catecholamines and
glucagon (15, 67, 68).
These data emphasise the complexity of the regulation of whole
body metabolism, and the role of AMPK being not only a peripheral
or a central mediator, but also a key enzyme in coordinating the
interaction between peripheral and central energy regulation.
Conclusions
Despite great advances in our understanding of hypothalamic
control of food intake in recent years, many questions remain
unanswered. It appears that AMPK plays an important role in
appetite regulation, with increased AMPK activation resulting in
increased food intake, decreased energy expenditure and, predict-
ably, increased body weight. The converse is also seen with
reduced AMPK activity causing decreased food intake. However,
these experimental models differ and any direct comparisons must
be made with caution. The effect of each of the treatments dis-
cussed on AMPK varies according to the tissue type, the duration
of exposure and the feeding conditions of the animal. For exam-
ple, leptin and metformin stimulate AMPK activity in skeletal mus-
cle but inhibit it in the hypothalamus, whereas ghrelin and
cannabinoids stimulate AMPK in the hypothalamus but inhibit it
in liver and adipose tissue (7). Even within the hypothalamus
itself, there is localisation of the effect of different compounds
on AMPK: leptin acting in the ARC and PVN, glucose and insulin
in the mediobasal and lateral hypothalamus as well as the ARC
and PVN (11). AMPK appears to have an alternative role in the
hypothalamic neurones because AMPK loss in AgRP neurones
leads to reduced body weight, whereas its loss in POMC neurones
leads to increased appetite and body weight (13), suggesting a
cell-speciﬁc role for this enzyme. The complexities of this system
are further demonstrated by some hormones affecting hypotha-
lamic AMPK in ad libitum feeding conditions [e.g. ghrelin or cann-
abinoids (27)], whereas others only have an effect after variable
time of fasting or re-feeding [e.g. leptin (11), adiponectin (42)].
A further complication could arise from the fact that the effect
of AMPK activators and inhibitors (AICAR, metformin and Com-
pound C) may not be speciﬁc to AMPK (4). Therefore, the results
obtained from studies using these agents should be interpreted
with caution. Appetite regulation and whole body energy homeo-
stasis remain challenging physiological processes and much
research is still needed in this ﬁeld. In particular, very little is
known about the intermediate players acting between hormones,
their receptors and AMPK and its upstream regulation. More work
is also needed to unravel the exact mechanisms by which AMPK
status affects food intake.
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